

Ric M Procyshyn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4477631/publications.pdf>

Version: 2024-02-01

137
papers

3,465
citations

186254
28
h-index

189881
50
g-index

142
all docs

142
docs citations

142
times ranked

3523
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis. <i>Microbial Biotechnology</i> , 2022, 16, 589-599.	1.7	27
2	Pain, opioid use, depressive symptoms, and mortality in adults living in precarious housing or homelessness: a longitudinal prospective study. <i>Pain</i> , 2022, 163, 2213-2223.	4.2	4
3	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. <i>Pharmacopsychiatry</i> , 2022, 55, 73-86.	3.3	107
4	Antipsychotic Drug-Induced Increases in Peripheral Catecholamines are Associated With Glucose Intolerance. <i>Frontiers in Pharmacology</i> , 2022, 13, 765905.	3.5	3
5	Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. <i>PLoS ONE</i> , 2022, 17, e0267808.	2.5	15
6	Differential effects of cannabis exposure during early versus later adolescence on the expression of psychosis in homeless and precariously housed adults. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 106, 110084.	4.8	7
7	Dynamic networks of psychotic symptoms in adults living in precarious housing or homelessness. <i>Psychological Medicine</i> , 2021, , 1-11.	4.5	3
8	A Focused Review of the Metabolic Side-Effects of Clozapine. <i>Frontiers in Endocrinology</i> , 2021, 12, 609240.	3.5	32
9	Relationship between clozapine dose and severity of obsessive-compulsive symptoms. <i>Medical Hypotheses</i> , 2021, 148, 110506.	1.5	1
10	Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis. <i>NPJ Schizophrenia</i> , 2021, 7, 29.	3.6	13
11	Component Processes of Decision Making in a Community Sample of Precariously Housed Persons: Associations With Learning and Memory, and Health-Risk Behaviors. <i>Frontiers in Psychology</i> , 2021, 12, 571423.	2.1	0
12	A ganglionic blocker and adrenoceptor ligands modify clozapine-induced insulin resistance. <i>Psychoneuroendocrinology</i> , 2021, 129, 105257.	2.7	3
13	Exercise and Worsening of Extrapyrimal Symptoms during Treatment with Long-Acting Injectable Antipsychotics. <i>Pharmacy (Basel, Switzerland)</i> , 2021, 9, 123.	1.6	3
14	Characterization of Bodily Pain and Use of Both Prescription and Non-Prescription Opioids in Tenants of Precarious Housing. <i>Substance Use and Misuse</i> , 2021, 56, 1951-1961.	1.4	5
15	Population pharmacokinetics and dosing of long-acting injectable antipsychotics. <i>Journal of Psychiatry and Neuroscience</i> , 2021, 46, E516-E517.	2.4	0
16	A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models. <i>PLoS ONE</i> , 2021, 16, e0246211.	2.5	6
17	Decreased medial entorhinal cortical thickness in olanzapine exposed female rats is not ameliorated by exercise. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 188, 172834.	2.9	0
18	Cognitive decline and mortality in a community-based sample of homeless and precariously housed adults: 9-year prospective study. <i>BJPsych Open</i> , 2020, 6, e21.	0.7	22

#	ARTICLE	IF	CITATIONS
19	Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines. <i>Frontiers in Psychiatry</i> , 2020, 11, 617428.	2.6	18
20	Associations of substance use, psychosis, and mortality among people living in precarious housing or homelessness: A longitudinal, community-based study in Vancouver, Canada. <i>PLoS Medicine</i> , 2020, 17, e1003172.	8.4	32
21	Clozapine-Associated Obsessive-Compulsive Symptoms and Their Management: A Systematic Review and Analysis of 107 Reported Cases. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 151-160.	8.8	19
22	How many clients with refractory psychosis are eligible for both cognitive-behaviour therapy and clozapine? A chart-review study. <i>Cogent Psychology</i> , 2019, 6, 1611208.	1.3	0
23	Cognitive Impairment in Marginally Housed Youth: Prevalence and Risk Factors. <i>Frontiers in Public Health</i> , 2019, 7, 270.	2.7	12
24	Cognitive profiles and associated structural brain networks in a multimorbid sample of marginalized adults. <i>PLoS ONE</i> , 2019, 14, e0218201.	2.5	9
25	A comparison of regional brain volumes and white matter connectivity in subjects with stimulant induced psychosis versus schizophrenia. <i>Psychopharmacology</i> , 2019, 236, 3385-3399.	3.1	10
26	Diffusion tensor imaging of neurocognitive profiles in a community cohort living in marginal housing. <i>Brain and Behavior</i> , 2019, 9, e01233.	2.2	7
27	Clozapine-induced obsessive-compulsive symptoms: mechanisms and treatment. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 71-72.	2.4	19
28	Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2019, 22, 548-566.	2.1	4
29	Characterization of mental health in cannabis dispensary users, using structured clinical interviews and standardized assessment instruments. <i>BMC Psychiatry</i> , 2019, 19, 335.	2.6	13
30	Volumes of the Hippocampal Formation Differentiate Component Processes of Memory in a Community Sample of Homeless and Marginally Housed Persons. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 548-562.	0.5	9
31	Management of sexual adverse effects induced by atypical antipsychotic medication. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, 287-288.	2.4	6
32	Association between Serum Lipids and Antipsychotic Response in Schizophrenia. <i>Current Neuropharmacology</i> , 2019, 17, 852-860.	2.9	26
33	Reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia. <i>Psychiatry Research</i> , 2018, 262, 28-33.	3.3	8
34	Exercise-induced hippocampal neurogenesis: 5-HT ₃ receptor antagonism by antipsychotics as a potential limiting factor in Schizophrenia. <i>Molecular Psychiatry</i> , 2018, 23, 2252-2253.	7.9	5
35	Effects of physical activity on the symptoms of Tourette syndrome: A systematic review. <i>European Psychiatry</i> , 2018, 48, 13-19.	0.2	18
36	Statin add-on therapy for schizophrenia: Is the effect the same for clozapine?. <i>Psychiatry Research</i> , 2018, 263, 289-290.	3.3	3

#	ARTICLE	IF	CITATIONS
37	Risk of hair loss with different antidepressants. <i>International Clinical Psychopharmacology</i> , 2018, 33, 44-48.	1.7	1
38	Clozapine, elevated heart rate and QTc prolongation. <i>Journal of Psychiatry and Neuroscience</i> , 2018, 43, 71-72.	2.4	18
39	Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis. <i>PLoS ONE</i> , 2018, 13, e0199758.	2.5	8
40	A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. <i>Child and Adolescent Psychiatry and Mental Health</i> , 2018, 12, 37.	2.5	17
41	Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review. <i>Frontiers in Neuroscience</i> , 2018, 12, 203.	2.8	47
42	Clinical and functional characteristics of young adults living in single room occupancy housing: preliminary findings from a 10-year longitudinal study. <i>Canadian Journal of Public Health</i> , 2018, 109, 204-214.	2.3	22
43	Reversal of Dopamine Supersensitivity as a Mechanism of Action of Clozapine. <i>Psychotherapy and Psychosomatics</i> , 2018, 87, 306-307.	8.8	11
44	Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review. <i>CNS Drugs</i> , 2018, 32, 917-938.	5.9	15
45	Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 349-356.	1.4	21
46	Housing First Improves Adherence to Antipsychotic Medication Among Formerly Homeless Adults With Schizophrenia: Results of a Randomized Controlled Trial. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw136.	4.3	21
47	Characterization of white matter integrity deficits in cocaine-dependent individuals with substance-induced psychosis compared with non-psychotic cocaine users. <i>Addiction Biology</i> , 2017, 22, 873-881.	2.6	12
48	A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. <i>Psychopharmacology</i> , 2017, 234, 1535-1547.	3.1	23
49	The Hotel Study—Clinical and Health Service Effectiveness in a Cohort of Homeless or Marginally Housed Persons. <i>Canadian Journal of Psychiatry</i> , 2017, 62, 482-492.	1.9	38
50	Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 102-104.	1.4	46
51	Effects of Exercise on Serum Triglycerides and Symptoms of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 273-274.	1.4	9
52	Structural brain markers are differentially associated with neurocognitive profiles in socially marginalized people with multimorbid illness. <i>Neuropsychology</i> , 2017, 31, 28-43.	1.3	13
53	Heart-rate response to alpha2-adrenergic receptor antagonism by antipsychotics. <i>Clinical Autonomic Research</i> , 2017, 27, 407-410.	2.5	5
54	Traumatic Brain Injury in a Community-Based Cohort of Homeless and Vulnerably Housed Individuals. <i>Journal of Neurotrauma</i> , 2017, 34, 3301-3310.	3.4	19

#	ARTICLE	IF	CITATIONS
55	Exercise-associated extrapyramidal symptoms during treatment with long-acting injectable antipsychotic medications: A case report. <i>Clinical Schizophrenia and Related Psychoses</i> , 2017, , .	1.4	2
56	Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review. <i>Current Neuropharmacology</i> , 2016, 15, 174-183.	2.9	63
57	A Tetra-Primer Amplification Refractory System Technique for the Cost-Effective and Novel Genotyping of Eight Single-Nucleotide Polymorphisms of the Catechol-O-Methyltransferase Gene. <i>Genetic Testing and Molecular Biomarkers</i> , 2016, 20, 465-470.	0.7	4
58	Risk of Extrapyramidal Adverse Events With Aripiprazole. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 472-474.	1.4	16
59	Proposing the Use of Partial AUC as an Adjunctive Measure in Establishing Bioequivalence Between Deltoid and Gluteal Administration of Long-Acting Injectable Antipsychotics. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2016, 41, 659-664.	1.6	8
60	Factors affecting severity of positive and negative symptoms of psychosis in a polysubstance using population with psychostimulant dependence. <i>Psychiatry Research</i> , 2016, 240, 336-342.	3.3	15
61	Subcortical grey matter alterations in cocaine dependent individuals with substance-induced psychosis compared to non-psychotic cocaine users. <i>Schizophrenia Research</i> , 2016, 176, 158-163.	2.0	10
62	Response to the Letter to the Editor on “Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?” <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 745-747.	1.4	0
63	Elevated clozapine plasma concentration secondary to a urinary tract infection: proposed mechanisms. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, E67-E68.	2.4	12
64	Breakthrough symptoms after switching long-acting injectable paliperidone palmitate from the gluteal to the deltoid site of administration. <i>Journal of Psychiatry and Neuroscience</i> , 2016, 41, E56-E57.	2.4	7
65	Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 447-449.	1.4	25
66	Development of a cost-efficient novel method for rapid, concurrent genotyping of five common single nucleotide polymorphisms of the brain derived neurotrophic factor (BDNF) gene by tetra-primer amplification refractory mutation system. <i>International Journal of Methods in Psychiatric Research</i> , 2015, 24, 235-244.	2.1	7
67	Dimenhydrinate Use Disorder With Chronic Psychosis. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 105-107.	1.4	3
68	White matter deficits assessed by diffusion tensor imaging and cognitive dysfunction in psychostimulant users with comorbid human immunodeficiency virus infection. <i>BMC Research Notes</i> , 2015, 8, 515.	1.4	26
69	Cognition and Plasma Ratio of Clozapine to <i>N</i> -desmethylclozapine in Patients With Clozapine-Resistant Schizophrenia. <i>American Journal of Psychiatry</i> , 2015, 172, 1259-1259.	7.2	11
70	Mortality from treatable illnesses in marginally housed adults: a prospective cohort study. <i>BMJ Open</i> , 2015, 5, e008876.	1.9	34
71	The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values. <i>CNS Drugs</i> , 2015, 29, 975-983.	5.9	14
72	Therapeutic Drug Levels of Second Generation Antipsychotics in Youth: A Systematic Review. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2015, 25, 234-245.	1.3	24

#	ARTICLE	IF	CITATIONS
73	Response trajectories to clozapine in a secondary analysis of pivotal trials support using treatment response to subtype schizophrenia. Canadian Journal of Psychiatry, 2015, 60, S19-25.	1.9	11
74	An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with Olanzapine. PLoS ONE, 2014, 9, e107116.	2.5	18
75	Neurocognitive profiles of marginally housed persons with comorbid substance dependence, viral infection, and psychiatric illness. Journal of Clinical and Experimental Neuropsychology, 2014, 36, 1009-1022.	1.3	18
76	Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment. Journal of Psychiatry and Neuroscience, 2014, 39, E32-E33.	2.4	3
77	Prevalence and Patterns of Antipsychotic Use in Youth at the Time of Admission and Discharge From an Inpatient Psychiatric Facility. Journal of Clinical Psychopharmacology, 2014, 34, 17-22.	1.4	18
78	Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. International Clinical Psychopharmacology, 2014, 29, 125-137.	1.7	41
79	Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 170-176.	4.8	22
80	Clozapine administered once versus twice daily: Does it make a difference?. Medical Hypotheses, 2014, 82, 225-228.	1.5	17
81	Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 673-682.	3.2	21
82	Cardiovascular effects of acute treatment with the antipsychotic drug olanzapine in rats. Vascular Pharmacology, 2014, 62, 143-149.	2.1	11
83	Antipsychotic and Psychostimulant Drug Combination Therapy in Attention Deficit/Hyperactivity and Disruptive Behavior Disorders: A Systematic Review of Efficacy and Tolerability. Current Psychiatry Reports, 2013, 15, 355.	4.5	44
84	Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness. Current Cardiovascular Risk Reports, 2013, 7, 283-287.	2.0	11
85	A retrospective study of antipsychotic drug switching in a pediatric population. BMC Psychiatry, 2013, 13, 248.	2.6	7
86	Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings. Drug and Alcohol Dependence, 2013, 129, 167-179.	3.2	336
87	Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and loperidone: A Comparison with Olanzapine. PLoS ONE, 2013, 8, e53459.	2.5	36
88	The Hotel Study: Multimorbidity in a Community Sample Living in Marginal Housing. American Journal of Psychiatry, 2013, 170, 1413-1422.	7.2	82
89	Antipsychotic polypharmacy increases metabolic dysregulation in female rats.. Experimental and Clinical Psychopharmacology, 2013, 21, 164-171.	1.8	18
90	Personalized Risk Assessment of Drug-Related Harm Is Associated with Health Outcomes. PLoS ONE, 2013, 8, e79754.	2.5	10

#	ARTICLE	IF	CITATIONS
91	Adverse events associated with switching antipsychotics. Journal of Psychiatry and Neuroscience, 2012, 37, E1-E2.	2.4	8
92	Antipsychotic Medications: Linking Receptor Antagonism to Neuropsychological Functioning in First Episode Psychosis. Journal of the International Neuropsychological Society, 2012, 18, 717-727.	1.8	16
93	Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system. , 2012, 135, 113-122.		125
94	Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. Journal of Psychiatry and Neuroscience, 2012, 37, 407-415.	2.4	52
95	Excessive Antipsychotic Dosing in a Canadian Outpatient Population. Psychiatric Services, 2011, 62, 682-683.	2.0	4
96	Withdrawal. Neuromethods, 2011, , 431-459.	0.3	0
97	Differential Effects of Alcohol Intoxication on S100B Levels Following Traumatic Brain Injury. Journal of Trauma, 2010, 68, 1065-1071.	2.3	8
98	A Comparison of Antipsychotic Drug-Defined Daily Doses Versus Chlorpromazine Equivalent Doses in Patients With or Without Extrapyramidal Motor Symptoms. Journal of Clinical Psychopharmacology, 2010, 30, 741-743.	1.4	11
99	Gender-specific profiles of tobacco use among non-institutionalized people with serious mental illness. BMC Psychiatry, 2010, 10, 101.	2.6	36
100	Long-acting injectable risperidone in treatment refractory patients: A 14-week open-label pilot study. Schizophrenia Research, 2010, 123, 273-275.	2.0	5
101	Smoking cessation interventions among individuals in methadone maintenance: A brief review. Journal of Substance Abuse Treatment, 2010, 38, 191-199.	2.8	41
102	A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 945-954.	4.8	65
103	Preclinical models of antipsychotic drug-induced metabolic side effects. Trends in Pharmacological Sciences, 2010, 31, 484-497.	8.7	97
104	Effect of hypertriglyceridemia on the pharmacokinetics and blood-brain barrier penetration of clozapine and nortriptyline following administration to rats. European Neuropsychopharmacology, 2010, 20, 545-552.	0.7	9
105	Medication Errors in Psychiatry. CNS Drugs, 2010, 24, 595-609.	5.9	42
106	Persistent Antipsychotic Polypharmacy and Excessive Dosing in the Community Psychiatric Treatment Setting. Journal of Clinical Psychiatry, 2010, 71, 566-573.	2.2	104
107	Community mental healthcare providers' attitudes and practices related to smoking cessation interventions for people living with severe mental illness. Patient Education and Counseling, 2009, 77, 289-295.	2.2	55
108	Predictors of starting to smoke cigarettes in patients with first episode psychosis. Schizophrenia Research, 2009, 108, 258-264.	2.0	23

#	ARTICLE	IF	CITATIONS
109	Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. <i>Current Medical Research and Opinion</i> , 2009, 25, 2121-2132.	1.9	16
110	Do serum lipids predict response to clozapine treatment?. <i>Journal of Psychiatry and Neuroscience</i> , 2009, 34, 168.	2.4	12
111	A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy. <i>Journal of Psychiatry and Neuroscience</i> , 2009, 34, 433-42.	2.4	19
112	Antipsychotic polypharmacy does not increase the risk for side effects. <i>Schizophrenia Research</i> , 2008, 98, 323-324.	2.0	15
113	Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. <i>Schizophrenia Research</i> , 2008, 100, 252-260.	2.0	70
114	Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada). <i>Current Therapeutic Research</i> , 2007, 68, 409-420.	1.2	2
115	Conceptual and Methodological Issues??in the Design of Clinical Trials??of Antipsychotics for the Treatment??of Schizophrenia. <i>CNS Drugs</i> , 2007, 21, 699-714.	5.9	28
116	Determination of Clozapine and its Metabolite, Norclozapine in Various Biological Matrices Using High-Performance Liquid Chromatography. <i>Drug Development and Industrial Pharmacy</i> , 2007, 33, 1158-1166.	2.0	15
117	Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. <i>Journal of Psychiatry and Neuroscience</i> , 2007, 32, 331-8.	2.4	66
118	Corrected QT Intervals in Newly Admitted Geriatric Psychiatric Patients: An Examination of Risk Factors. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 371-376.	1.9	6
119	Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia. <i>New England Journal of Medicine</i> , 2006, 354, 472-482.	27.0	249
120	The Effects of Competitive Displacement on Haloperidol's Plasma Distribution in Normolipidemic and Hyperlipidemic Plasma. <i>Drug Development and Industrial Pharmacy</i> , 2005, 31, 901-905.	2.0	6
121	Competitive Displacement of Clozapine from Plasma Proteins in Normolipidemic and Hyperlipidemic Plasma Samples: Clinical Implications. <i>Drug Development and Industrial Pharmacy</i> , 2005, 31, 331-337.	2.0	8
122	Patterns of Antipsychotic Utilization in a Tertiary Care Psychiatric Institution. <i>Pharmacopsychiatry</i> , 2004, 37, 12-17.	3.3	49
123	Smoking, anticholinergics and schizophrenia. <i>Schizophrenia Research</i> , 2004, 67, 313-314.	2.0	2
124	Clozapine's effects on body weight and resting metabolic rate: a case series. <i>Schizophrenia Research</i> , 2004, 66, 159-162.	2.0	23
125	Prevalence and Outcomes of Pharmaceutical Industryâ€”Sponsored Clinical Trials Involving Clozapine, Risperidone, or Olanzapine. <i>Canadian Journal of Psychiatry</i> , 2004, 49, 601-606.	1.9	47
126	The influence of dyslipidemia on the plasma protein and lipoprotein distribution of haloperidol. <i>European Neuropsychopharmacology</i> , 2003, 13, 33-37.	0.7	8

#	ARTICLE	IF	CITATIONS
127	Generic Clozapine. Pharmacoeconomics, 2003, 21, 1-11.	3.3	12
128	Concomitant clozapine reduces smoking in patients treated with risperidone. European Neuropsychopharmacology, 2002, 12, 77-80.	0.7	38
129	Olanzapine associated weight gain, Hyperglycemia and Neuroleptic Malignant Syndrome: case report. International Journal of Geriatric Psychiatry, 2002, 17, 326-328.	2.7	19
130	Plasma Protein and Lipoprotein Distribution of Clozapine. American Journal of Psychiatry, 2001, 158, 949-951.	7.2	30
131	Antipsychotic Polypharmacy: A Survey of Discharge Prescriptions from a Tertiary Care Psychiatric Institution. Canadian Journal of Psychiatry, 2001, 46, 334-339.	1.9	111
132	Pharmacoeconomics of Clozapine, Risperidone and Olanzapine. CNS Drugs, 2000, 13, 47-76.	5.9	12
133	Theoretical Basis for Loxapine Augmentation in Risperidone Partial Responders. Clinical Drug Investigation, 2000, 19, 257-266.	2.2	3
134	Valproic acid for seizure prophylaxis during clozapine therapy: Where's the evidence?. International Journal of Psychiatry in Clinical Practice, 1999, 3, 249-251.	2.4	5
135	DR. Procyshyn replies. Clinical Therapeutics, 1999, 21, 925-930.	2.5	0
136	Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clinical Therapeutics, 1998, 20, 1203-1217.	2.5	46
137	Engineering Magnesium Selectivity in the Helixâ€Loopâ€Helix Calcium-Binding Motif. Archives of Biochemistry and Biophysics, 1995, 323, 115-119.	3.0	23